Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011 (2011), Article ID 280502, 7 pages
http://dx.doi.org/10.4061/2011/280502
Review Article

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

Instituto de Química Médica, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain

Received 17 March 2011; Accepted 3 May 2011

Academic Editor: Peter Crouch

Copyright © 2011 Ana Martinez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. C. Marques, C. R. Oliveira, T. F. Outeiro, and C. M. Pereira, “Alzheimer's disease: the quest to understand complexity,” The The Journal of Alzheimer's Disease, vol. 21, no. 2, pp. 373–383, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. J. Micheau and A. Marighetto, “Acetylcholine and memory: a long, complex and chaotic but still living relationship,” Behavioural Brain Research, vol. 221, no. 2, pp. 424–429, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. E. Giacobini, “Cholinesterase inhibitors stabilize Alzheimer disease,” Neurochemical Research, vol. 25, no. 9-10, pp. 1185–1190, 2000. View at Google Scholar · View at Scopus
  4. M. Shanks, M. Kivipelto, R. Bullock, and R. Lane, “Cholinesterase inhibition: is there evidence for disease-modifying effects?” Current Medical Research and Opinion, vol. 25, no. 10, pp. 2439–2446, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. J. Selkoe, “Alzheimer's disease: genotypes, phenotype, and treatments,” Science, vol. 275, no. 5300, pp. 630–631, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Armstrong, “The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease,” Folia Neuropathologica, vol. 47, no. 4, pp. 289–299, 2009. View at Google Scholar · View at Scopus
  7. D. Saumier, A. Duong, D. Haine, D. Garceau, and J. Sampalis, “Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the alphase study,” Journal of Nutrition, Health & Aging, vol. 13, no. 9, pp. 808–812, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Vellas, “Tarenflurbil for Alzheimer's disease: a “shot on goal” that missed,” The Lancet Neurology, vol. 9, no. 3, pp. 235–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. N. F. Schor, “What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us,” Annals of Neurology, vol. 69, no. 2, pp. 237–239, 2011. View at Publisher · View at Google Scholar · View at PubMed
  10. K. Iqbal and I. Grundke-Iqbal, “Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention,” Annals of the New York Academy of Sciences, vol. 777, pp. 132–138, 1996. View at Google Scholar · View at Scopus
  11. T. Del Ser, “Phase IIa clinical trial on Alzheimer’s disease with NP12, a GSK-3 inhibitor,” in Alzheimer's Dementia, vol 6, p S147, 2010.
  12. D. I. Perez, C. Gil, and A. Martinez, “Tau protein kinases inhibitors: from the bench to the clinical trials,” in Emerging Drugs and Targets for Alzheimer's Disease, A. Martinez, Ed., vol. 1, pp. 173–194, Royal Society of Chemistry, 2010. View at Google Scholar
  13. F. Plattner, M. Angelo, and K. P. Giese, “The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation,” The Journal of Biological Chemistry, vol. 281, no. 35, pp. 25457–25465, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Hooper, R. Killick, and S. Lovestone, “The GSK3 hypothesis of Alzheimer's disease,” Journal of Neurochemistry, vol. 104, no. 6, pp. 1433–1439, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. M. de la Monte, M. Tong, N. Lester-Coll, M. Plater Jr., and J. R. Wands, “Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease,” The Journal of Alzheimer's Disease, vol. 10, no. 1, pp. 89–109, 2006. View at Google Scholar · View at Scopus
  16. A. Takashima, M. Murayama, O. Murayama et al., “Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9637–9641, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Takashima, “Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in adult brain,” Journal of Pharmacological Sciences, vol. 109, no. 2, pp. 174–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Z. Wang, J. Brown, and M. Martin, “Glycogen synthase kinase 3: a point of convergence for the host inflammatory response,” Cytokine, vol. 53, no. 2, pp. 130–140, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. K. Leroy, Z. Yilmaz, and J. P. Brion, “Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration,” Neuropathology and Applied Neurobiology, vol. 33, no. 1, pp. 43–55, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. Martinez and D. I. Perez, “GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?” The Journal of Alzheimer's Disease, vol. 15, no. 2, pp. 181–191, 2008. View at Google Scholar · View at Scopus
  21. E. M. Hur and F. Q. Zhou, “GSK3 signalling in neural development,” Nature Reviews Neuroscience, vol. 11, no. 8, pp. 539–551, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. C. Xu, N. G. Kim, and B. M. Gumbiner, “Regulation of protein stability by GSK3 mediated phosphorylation,” Cell Cycle, vol. 8, no. 24, pp. 4032–4039, 2009. View at Google Scholar · View at Scopus
  23. M. Bouskila, M. F. Hirshman, J. Jensen, L. J. Goodyear, and K. Sakamoto, “Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle,” American Journal of Physiology, vol. 294, no. 1, pp. E28–E35, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. E. Nikoulina, T. P. Ciaraldi, S. Mudaliar, P. Mohideen, L. Carter, and R. R. Henry, “Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes,” Diabetes, vol. 49, no. 2, pp. 263–271, 2000. View at Google Scholar · View at Scopus
  25. S. E. Nikoulina, T. P. Ciaraldi, S. Mudaliar, L. Carter, K. Johnson, and R. R. Henry, “Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle,” Diabetes, vol. 51, no. 7, pp. 2190–2198, 2002. View at Google Scholar · View at Scopus
  26. J. R. Woodgett, “Glycogen synthase kinase 3: an introductory synopsis,” in Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors, A. Martinez, A. Castro, and M. Medina, Eds., pp. 3–23, John Wiley & Sons, Hoboken, NJ, USA, 2006. View at Google Scholar
  27. D. Wu and W. Pan, “GSK3: a multifaceted kinase in Wnt signaling,” Trends in Biochemical Sciences, vol. 35, no. 3, pp. 161–168, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. D. Gould, N. A. Gray, and H. K. Manji, “Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice,” Pharmacological Research, vol. 48, no. 1, pp. 49–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Phukan, V. S. Babu, A. Kannoji, R. Hariharan, and V. N. Balaji, “GSK3beta: role in therapeutic landscape and development of modulators,” British Journal of Pharmacology, vol. 160, no. 1, pp. 1–19, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. Martinez, “Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs,” Medicinal Research Reviews, vol. 28, no. 5, pp. 773–796, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. Martinez, A. Castro, I. Dorronsoro, and M. Alonso, “Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation,” Medicinal Research Reviews, vol. 22, no. 4, pp. 373–384, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. P. Bamborough, D. Drewry, G. Harper, G. K. Smith, and K. Schneider, “Assessment of chemical coverage of kinome space and its implications for kinase drug discovery,” Journal of Medicinal Chemistry, vol. 51, no. 24, pp. 7898–7914, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Martinez, M. Alonso, A. Castro, C. Perez, and F. J. Moreno, “First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1292–1299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Dugo, M. Collin, and C. Thiemermann, “Glycogen synthase kinase 3 beta as a target for the therapy of shock and inflammation,” Shock, vol. 27, no. 2, pp. 113–123, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. M. L. Guzman, X. J. Li, C. A. Corbett et al., “Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8),” Blood, vol. 110, no. 13, pp. 4436–4444, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. Hamann, D. Alonso, E. Martin-Aparicio et al., “Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease,” Journal of Natural Products, vol. 70, no. 9, pp. 1397–1405, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. D. Alonso and A. Martinez, “Marine compounds as a new source for glycogen synthase kinase 3 inhibitors,” in Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors, A. Martinez, A. Castro, and M. Medina, Eds., pp. 307–331, John Wiley & Sons, Hoboken, NJ, USA, 2006. View at Google Scholar
  38. J. Peng, S. Kudrimoti, S. Prasanna et al., “Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections,” Journal of Medicinal Chemistry, vol. 53, no. 1, pp. 61–76, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. G. Ermondi, G. Caron, I. G. Pintos et al., “An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive Glycogen Synthase Kinase 3[beta] (GSK-3[beta]) inhibitors,” European Journal of Medicinal Chemistry, vol. 46, no. 3, pp. 860–869, 2011. View at Publisher · View at Google Scholar · View at PubMed
  40. H. Eldar-Finkelman, A. Licht-Murava, S. Pietrokovski, and M. Eisenstein, “Substrate competitive GSK-3 inhibitors—strategy and implications,” Biochimica et Biophysica Acta, vol. 1804, no. 3, pp. 598–603, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. H. Eldar-Finkelman and M. Eisenstein, “Peptide inhibitors targeting protein kinases,” Current Pharmaceutical Design, vol. 15, no. 21, pp. 2463–2470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Shapira, A. Licht, A. Milman, C. G. Pick, E. Shohami, and H. Eldar-Finkelman, “Role of glycogen synthase kinase-3 beta in early depressive behavior induced by mild traumatic brain injury,” Molecular and Cellular Neuroscience, vol. 34, no. 4, pp. 571–577, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. O. Kaidanovich-Beilin and H. Eldar-Finkelman, “Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 1, pp. 17–24, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. C. P. Belani, “The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors,” Cancer Investigation, vol. 28, no. 4, pp. 413–423, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S. Conde, D. I. Perez, A. Martinez, C. Perez, and F. J. Moreno, “Thienyl and Phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3 beta) from a library of compound searching,” Journal of Medicinal Chemistry, vol. 46, no. 22, pp. 4631–4633, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. D. I. Perez, S. Conde, C. Perez et al., “Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools,” Bioorganic & Medicinal Chemistry, vol. 17, no. 19, pp. 6914–6925, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. D. I. Pérez, V. Palomo, C. Pérez et al., “Switching reversibility to irreversibility in GSK-3 inhibitors: clues for specific design of new compounds,” Journal of Medicinal Chemistry, vol. 54, no. 12, pp. 4042-4056, 2011.
  48. J. R. Woodgett, “Use of peptide substrates for affinity purification of protein-serine kinases,” Analytical Biochemistry, vol. 180, no. 2, pp. 237–241, 1989. View at Google Scholar · View at Scopus
  49. I. Hers, J. M. Tavare, and R. M. Denton, “The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity,” FEBS Letters, vol. 460, no. 3, pp. 433–436, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Martinez, A. Castro, I. Cardelus, J. Llenas, and J. M. Palacios, “Arylimino-1,2,4-Thiadiazolidinones: a new family of potassium channel openers,” Bioorganic & Medicinal Chemistry, vol. 5, no. 7, pp. 1275–1283, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Martinez, D. Alonso, A. Castro et al., “Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds,” Archiv der Pharmazie, vol. 332, no. 6, pp. 191–194, 1999. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Martinez, E. Fernandez, A. Castro et al., “N-benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors,” European Journal of Medicinal Chemistry, vol. 35, no. 10, pp. 913–922, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Martinez, A. Castro, C. Perez et al., “Heterocyclic inhibitors of glycogen synthase kinase 3,” WO01/85685.
  54. H. C. Zhang, H. Ye, B. R. Conway et al., “3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 12, pp. 3245–3250, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. T. A. Engler, S. Malhotra, T. P. Burkholder et al., “The development of potent and selective bisarylmaleimide GSK3 inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 15, no. 4, pp. 899–903, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. A. Martinez, M. Alonso, A. Castro et al., “SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors,” Journal of Medicinal Chemistry, vol. 48, no. 23, pp. 7103–7112, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Martinez, M. Alonso, A. Castro, and I. Dorronsoro, “GSK-3 inhibitors in Alzheimer's disease: TDZDs, from the discovery to clinical trials,” in Medicinal Chemistry of Alzheimer Disease, A. Martinez, Ed., pp. 225–253, Transworld Research Network, Kerala, India, 2008. View at Google Scholar
  58. http://www.noscira.com/prensa.cfm?mS=237&mSS=616.
  59. http://clinicaltrials.gov/ct2/show/NCT01049399?term=tideglusib&rank=1.
  60. R. Luna-Medina, M. Cortes-Canteli, S. Sanchez-Galiano et al., “NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders,” Journal of Neuroscience, vol. 27, no. 21, pp. 5766–5776, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. E. M. Ribe, M. Perez, B. Puig et al., “Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice,” Neurobiology of Disease, vol. 20, no. 3, pp. 814–822, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. L. Sereno, M. Coma, M. Rodriguez et al., “A novel GSK-3 beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo,” Neurobiology of Disease, vol. 35, no. 3, pp. 359–367, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. Bolos, S. Fernandez, and I. Torres-Aleman, “Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels,” The Journal of Biological Chemistry, vol. 285, no. 23, pp. 17693–17700, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. I. Torres-Aleman, “Targeting insulin-like growth factor-1 to treat Alzheimer's disease,” Expert Opinion on Therapeutic Targets, vol. 11, no. 12, pp. 1535–1542, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. Medina and J. Avila, “Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease,” Current Pharmaceutical Design, vol. 16, no. 25, pp. 2790–2798, 2010. View at Google Scholar
  66. A. Hye, F. Kerr, N. Archer et al., “Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease,” Neuroscience Letters, vol. 373, no. 1, pp. 1–4, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus